Skip to main content
Clinical Trials/JPRN-jRCTs031230041
JPRN-jRCTs031230041
Active, not recruiting
未知

A Clinical Study on the Efficacy and Safety of a New Method of Fecal Microbiota Transplantation (FMT) for Treatment of Autism Spectrum Disorder (ASD)

Tanaka Yoshimu0 sites30 target enrollmentApril 18, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Autism Spectrum Disorder
Sponsor
Tanaka Yoshimu
Enrollment
30
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 18, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tanaka Yoshimu

Eligibility Criteria

Inclusion Criteria

  • 1\. Children between the ages of 5 and 12,
  • regardless of gender, who have recently been
  • diagnosed with ASD by a board\-certified pediatric
  • neurologist of The Japanese Society of Child
  • Neurology, a board\-certified psychiatrist of
  • The Japanese Society for Psychiatry and Neurology,
  • a board\-certified member of The Japanese Society
  • for Child and Adolescent Psychiatry, or a
  • board\-certified member of Japanese Society of
  • Pediatric Psychiatry and Neurology.

Exclusion Criteria

  • 1\. Currently on treatment with medicines.
  • 2\. Received antibiotics (excluding topical
  • antibiotics) within the last three months.
  • 3\. Received fecal microbiota transplantation
  • within the last 12 months.
  • 4\. Children with a single gene disorder
  • (Fragile X, Rett Syndrome, Joubert Syndrome,
  • etc. which may affect the evaluation of ASD).
  • 5\. Children with neurosurgical or neurological
  • 6\. Currently on tube feeding.

Outcomes

Primary Outcomes

Not specified

Similar Trials